Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Screening Individuals and Families at High Risk for Hematologic Cancers
This study is currently recruiting participants.
Verified by National Cancer Institute (NCI), April 2007
Sponsored by: National Cancer Institute (NCI)
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT00052234
  Purpose

RATIONALE: Evaluating genetic and environmental factors in individuals and families at high risk of developing hematologic cancer may help doctors plan more effective treatments.

PURPOSE: Screening trial to determine if genetic and environmental factors contribute to the development of hematologic cancer in individuals and families at high risk for cancer.


Condition Intervention
Leukemia
Lymphoma
Lymphoproliferative Disorder
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Diseases
Procedure: counseling
Procedure: evaluation of cancer risk factors
Procedure: gene expression profiling
Procedure: genetic linkage analysis
Procedure: laboratory biomarker analysis
Procedure: questionnaire administration

Genetics Home Reference related topics: aceruloplasminemia hemophilia
MedlinePlus related topics: Cancer Hodgkin's Disease Leukemia, Adult Acute Leukemia, Adult Chronic Leukemia, Childhood Lymphoma Multiple Myeloma
U.S. FDA Resources
Study Type: Observational
Official Title: Clinical, Laboratory And Epidemiologic Characterization Of Individuals And Families At High Risk Of Hematologic Cancer

Further study details as provided by National Cancer Institute (NCI):

Estimated Enrollment: 3000
Study Start Date: June 2002
Estimated Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)
Detailed Description:

OBJECTIVES:

  • Ascertain individuals at high risk for hematologic malignancy because of personal or family medical history.
  • Evaluate and define the clinical spectrum and natural history of disease in syndromes predisposing these individuals and families to hematologic cancer.
  • Evaluate the potential precursor states of malignancy in families at risk.
  • Quantify the risks of specific tumors in family members of this high-risk population and define syndromic constellations.
  • Identify, map, characterize, clone, and determine function of tumor susceptibility genes in this high-risk population.
  • Validate and test associations of biomarkers with risk in these individuals.
  • Identify genetic determinants, environmental factors, and gene-environmental interactions conferring cancer risk in individuals and families.
  • Identify differences and similarities between the familial and sporadic condition in this high-risk population.
  • Educate and counsel study participants about their risk of hematologic malignancy including prevention recommendations and early detection activities when known.

OUTLINE: One family member completes a family history questionnaire. Participants may undergo limited physical exams, imaging studies, and skin or bone marrow biopsy.

Blood is collected for localizing genetic loci, identifying genes, and evaluating genotype/phenotype correlations. Buccal cells are obtained for germline DNA extraction.

Participants receive counseling and education for cancer prevention, risk reduction, and early detection.

Participants are followed approximately annually for as long as possible.

PROJECTED ACCRUAL: A total of 3,000 patients will be accrued for this study.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • Meets one of the following criteria:

    • Family or personal medical history of hematologic/lymphoproliferative malignancy of an unusual type, pattern, or number
    • Known or suspected factor(s) predisposing to hematologic malignancy
    • Genetic and/or congenital (e.g., birth defects, metabolic phenotype, chromosomal anomalies, or Mendelian traits associated with tumors)
    • Environmental exposure (e.g., medications, occupation, radiation, diet, or infectious agents)
    • Unusual demographic features (e.g., very young age at onset or multiple tumors)
  • Familial aggregation of any of the following:

    • Chronic lymphocytic leukemia
    • Waldenstrom's macroglobulinemia (WM)
    • Non-Hodgkin's lymphoma
    • Hodgkin's lymphoma
    • Mixed hematologic and lymphoproliferative diseases
    • Any other hematologic cancer
  • At least 2 living affected family members required for familial neoplasms

    • For WM, one case plus a living first-degree relative with an autoimmune condition is required

PATIENT CHARACTERISTICS:

Age

  • Any age

Performance status

  • Not specified

Life expectancy

  • Not specified

Hematopoietic

  • Not specified

Hepatic

  • Not specified

Renal

  • Not specified

PRIOR CONCURRENT THERAPY:

Biologic therapy

  • Not specified

Chemotherapy

  • Not specified

Endocrine therapy

  • Not specified

Radiotherapy

  • Not specified

Surgery

  • Not specified
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00052234

Locations
United States, Maryland
NCI - Division of Cancer Epidemiology and Genetics Recruiting
Bethesda, Maryland, United States, 20892
Contact: Genetic Epidemiology Branch Referral Nurse     800-518-8474        
NCI - Genetic Epidemiology Branch Recruiting
Bethesda, Maryland, United States, 20892
Contact: Mary L. McMaster, MD     301-496-4375     mm349q@nih.gov    
Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office Recruiting
Bethesda, Maryland, United States, 20892-1182
Contact: Clinical Trials Office - Warren Grant Magnusen Clinical Center     888-NCI-1937        
Sponsors and Collaborators
Investigators
Study Chair: Neil E. Caporaso, MD NCI - Genetic Epidemiology Branch
  More Information

Clinical trial summary from the National Cancer Institute's PDQ® database  This link exits the ClinicalTrials.gov site
Featured trial article  This link exits the ClinicalTrials.gov site

Publications of Results:
Other Publications:
Caporaso N, Marti GE, Goldin L. Perspectives on familial chronic lymphocytic leukemia: genes and the environment. Semin Hematol. 2004 Jul;41(3):201-6. Review.
Chatterjee N, Hartge P, Cerhan JR, Cozen W, Davis S, Ishibe N, Colt J, Goldin L, Severson RK. Risk of non-Hodgkin's lymphoma and family history of lymphatic, hematologic, and other cancers. Cancer Epidemiol Biomarkers Prev. 2004 Sep;13(9):1415-21.
Goldin LR, Pfeiffer RM, Gridley G, Gail MH, Li X, Mellemkjaer L, Olsen JH, Hemminki K, Linet MS. Familial aggregation of Hodgkin lymphoma and related tumors. Cancer. 2004 May 1;100(9):1902-8.
Goldin LR, Pfeiffer RM, Li X, Hemminki K. Familial risk of lymphoproliferative tumors in families of patients with chronic lymphocytic leukemia: results from the Swedish Family-Cancer Database. Blood. 2004 Sep 15;104(6):1850-4. Epub 2004 May 25.
Pfeiffer RM, Goldin LR, Chatterjee N, Daugherty S, Hemminki K, Pee D, X LI, Gail MH. Methods for testing familial aggregation of diseases in population-based samples: application to Hodgkin lymphoma in Swedish registry data. Ann Hum Genet. 2004 Sep;68(Pt 5):498-508.
Goldin LR, Ishibe N, Sgambati M, Marti GE, Fontaine L, Lee MP, Kelley JM, Scherpbier T, Buetow KH, Caporaso NE. A genome scan of 18 families with chronic lymphocytic leukaemia. Br J Haematol. 2003 Jun;121(6):866-873.
Ishibe N, Prieto D, Hosack DA, Lempicki RA, Goldin LR, Raffeld M, Marti GE, Caporaso NE. Telomere length and heavy-chain mutation status in familial chronic lymphocytic leukemia. Leuk Res. 2002 Sep;26(9):791-4.

Study ID Numbers: CDR0000256894, NCI-02-C-0210
Study First Received: January 24, 2003
Last Updated: December 11, 2008
ClinicalTrials.gov Identifier: NCT00052234  
Health Authority: Unspecified

Keywords provided by National Cancer Institute (NCI):
AIDS-related lymphoma
Hodgkin lymphoma during pregnancy
T-cell large granular lymphocyte leukemia
Waldenstrom macroglobulinemia
acute undifferentiated leukemia
adult Hodgkin lymphoma
adult T-cell leukemia/lymphoma
adult acute lymphoblastic leukemia
adult acute myeloid leukemia
adult diffuse large cell lymphoma
adult diffuse mixed cell lymphoma
adult diffuse small cleaved cell lymphoma
adult Burkitt lymphoma
adult immunoblastic large cell lymphoma
adult lymphoblastic lymphoma
anaplastic large cell lymphoma
angioimmunoblastic T-cell lymphoma
childhood Hodgkin lymphoma
childhood acute lymphoblastic leukemia
childhood non-Hodgkin lymphoma
childhood acute myeloid leukemia/other myeloid malignancies
chronic lymphocytic leukemia
chronic myelogenous leukemia
chronic myelomonocytic leukemia
cutaneous T-cell non-Hodgkin lymphoma
grade 1 follicular lymphoma
grade 2 follicular lymphoma
grade 3 follicular lymphoma
hairy cell leukemia
intraocular lymphoma

Study placed in the following topic categories:
Juvenile myelomonocytic leukemia
Sezary syndrome
Chronic myelogenous leukemia
Chronic myelomonocytic leukemia
Primary effusion lymphoma
Hodgkin lymphoma, adult
Lymphoma, Mantle-Cell
Lymphoma, small cleaved-cell, diffuse
Lymphoma, large-cell, immunoblastic
Central nervous system lymphoma, primary
Mycoses
Preleukemia
Hemorrhagic Disorders
Leukemia, Prolymphocytic
Multiple myeloma
Lymphoma, AIDS-Related
Leukemia, Lymphocytic, Chronic, B-Cell
Neoplasm Metastasis
Lymphoma, Large-Cell, Anaplastic
Acute myeloid leukemia, adult
Hodgkin Disease
Chronic lymphocytic leukemia
Myelodysplastic syndromes
Lymphoma, Large B-Cell, Diffuse
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Immunoproliferative Disorders
Hematologic Diseases
Leukemia, B-cell, chronic
Leukemia, Myelomonocytic, Chronic
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

Additional relevant MeSH terms:
Neoplasms
Neoplasms by Site
Pathologic Processes
Disease
Neoplasms by Histologic Type
Immune System Diseases
Syndrome
Cardiovascular Diseases

ClinicalTrials.gov processed this record on January 16, 2009